A new discovery offers hope for Huntington’s disease. This discovery provides hope that a DNA repair process may help slow or ...

Several neuropsychiatric disorders such as attention deficit-hyperactivity disorder (ADHD), autism spectrum disorder (ASD), as well as neurological diseases such as spinocerebellar ataxia type 3 (SCA3 ...

According to Biohaven, the FDA’s decision on the NDA is expected during the 3rd quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of a polyglutamine tract in ataxin-1. In affected neurons of SCA1 patients and ...

And it came to pass on the day that Moses had fully set up the Tabernacle, and had anointed it, and sanctified it (set it apart for, dedicated it for sacred use), and all the instruments thereof, both ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Labroots is thrilled to announce the 13th Annual Event in the Neuroscience Virtual Event Series, streaming live on March 5th, 2025. Join us as we dive into the captivating world of neuroscience, ...

These deficits may reflect alterations in spinocerebellar tracts that innervate the cerebellum primarily through the inferior cerebellar peduncle (Cheng et al., 2010). Further studies examining ...

Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...